4//SEC Filing
Schneiderman Daniel H 4
Accession 0001415889-21-003429
CIK 0001604191other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 5:09 PM ET
Size
13.6 KB
Accession
0001415889-21-003429
Insider Transaction Report
Form 4
Schneiderman Daniel H
CHIEF FINANCIAL OFFICER
Transactions
- Other
Stock option (right to buy)
2021-06-30−35,006→ 0 totalExercise: $0.85Exp: 2030-07-15→ Common Stock, par value $0.0001 per share (35,006 underlying) - Award
Stock option (right to buy)
2021-06-30+250,000→ 250,000 totalExercise: $0.85Exp: 2031-06-30→ Common Stock, par value $0.0001 per share (250,000 underlying) - Award
Stock option (right to buy)
2021-06-30+35,006→ 35,006 totalExercise: $0.85Exp: 2031-06-30→ Common Stock, par value $0.0001 per share (35,006 underlying) - Other
Stock option (right to buy)
2021-06-30−250,000→ 0 totalExercise: $0.85Exp: 2030-07-15→ Common Stock, par value $0.0001 per share (250,000 underlying)
Footnotes (5)
- [F1]On June 30, 2021, the board of directors of AzurRx BioPharma, Inc. (the "Company") rescinded and cancelled stock option awards previously made to Mr. Schneiderman on July 16, 2020 covering an aggregate of 285,006 shares under the Company's Amended and Restated 2014 Omnibus Equity Incentive Plan and granted new stock options under the Company's 2020 Omnibus Equity Incentive Plan, as amended and restated, on substantially similar terms to the rescinded stock options.
- [F2]The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on February 3, 2020, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date.
- [F3]The stock option vests (i) with respect to 17,502 shares immediately and (ii) with respect to 17,504 shares over a term of 19 months in 19 equal monthly installments, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date.
- [F4]The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on August 16, 2020, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date.
- [F5]The stock option vests (i) with respect to 79,860 shares immediately and (ii) with respect to 170,140 shares over a term of 2 years and 1 month in 25 equal monthly installments, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date.
Documents
Issuer
AzurRx BioPharma, Inc.
CIK 0001604191
Entity typeother
Related Parties
1- filerCIK 0001565536
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 5:09 PM ET
- Size
- 13.6 KB